Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.

Thumbnail
Date
2009-01
ICR Author
Ashworth, Alan
Lord, Christopher
Author
Iorns, E
Lord, CJ
Ashworth, A
Type
Journal Article
Metadata
Show full item record
Abstract
Tamoxifen is the most commonly used drug to treat breast cancer and acts by blocking ERalpha (oestrogen receptor alpha) signalling. Although highly effective, its usefulness is limited by the development of resistance. Given this, strategies that limit resistance by sensitizing cells to tamoxifen may be of use in the clinic. To gain insight into how this might be achieved, we used chemical and genetic screens to identify targets and small-molecule inhibitors that cause tamoxifen sensitization. A high-throughput genetic screen, using an RNA interference library targeting 779 kinases and related proteins, identified the PDK1 (phosphoinositide-dependent kinase 1) signalling pathway as a strong determinant of sensitivity to multiple ERalpha antagonists, including tamoxifen. A chemical screen using existing drugs and known kinase inhibitors also identified inhibitors of the PDK1 pathway, including triciribine and tetrandrine. Aside from identifying novel agents and targets for tamoxifen sensitization, this approach also provides evidence that performing chemical and genetic screens in parallel may be useful.
URI
https://repository.icr.ac.uk/handle/internal/2061
DOI
https://doi.org/10.1042/bj20081682
Collections
  • Breast Cancer Research
  • Molecular Pathology
Subject
Cell Line, Tumor
Humans
Tamoxifen
Benzylisoquinolines
Estrogen Antagonists
Protein-Serine-Threonine Kinases
Ribonucleosides
Flow Cytometry
Signal Transduction
Cell Survival
RNA Interference
Pyruvate Dehydrogenase Acetyl-Transferring Kinase
Research team
Gene Function
Language
eng
License start date
2009-01
Citation
The Biochemical journal, 2009, 417 (1), pp. 361 - 370

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.